Obermair, Andreas, Nicklin, Jim, Gebski, Val, Hayes, Sandra C., Graves, Nicholas, Mileshkin, Linda, Lin, Ming Yin, Beale, Phillip, Baxter, Eva, Robledo, Kristy, Salomon, Carlos, Hanna, George B. and Janda, Monika (2021). A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecologic Cancer, 31 (12), 1595-1601. doi: 10.1136/ijgc-2021-003029
Journal Article: Fertility-sparing treatment in early endometrial cancer: current state and future strategies
Obermair, Andreas, Baxter, Eva, Brennan, Donal J., McAlpine, Jessica N., Muellerer, Jennifer J., Amant, Frédéric, van Gent, Mignon D. J. M., Coleman, Robert L., Westin, Shannon N., Yates, Melinda S., Krakstad, Camilla and Janda, Monika (2020). Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 63 (4), 417-431. doi: 10.5468/ogs.19169
Journal Article: Improving response to progestin treatment of low-grade endometrial cancer
Baxter, Eva, Brennan, Donal J, McAlpine, Jessica N, Mueller, Jennifer J, Amant, Frédéric, van Gent, Mignon D J M, Huntsman, David G, Coleman, Robert L, Westin, Shannon N, Yates, Melinda S, Krakstad, Camilla, Quinn, Michael A, Janda, Monika and Obermair, Andreas (2020). Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecologic Cancer, 30 (11) ijgc-2020-001309, ijgc-2020. doi: 10.1136/ijgc-2020-001309
(2024–2028) NHMRC Clinical Trials and Cohort Studies Grants
Biomarkers in gynaecological cancer
Gynaecological cancers are the third most common cancer type diagnosed in Australian women. Each year over 6,700 Australian women and girls are diagnosed with gynaecological cancer and almost a third will not survive their disease.
We have a PhD opportunity available at the Queensland Centre for Gynaecological Cancer (QCGC) Research focusing on discovering and validating biomarkers that improve outcomes for women with gynaecological cancer. This project will involve working with clinical samples, conducting laboratory work, and analysing data.
The successful applicant will work as part of the QCGC Research team at the Centre for Clinical Research, as well as collaborate with researchers, clinicians, consumers, and stakeholders from other organisations, including hospitals, pathology providers and the community.
Improving outcomes for women experiencing gynaecological cancer
Endometrial cancer originates from the inner layer of the uterus and is the fifth most common cancer in women. In Australia, the incidence is >3,000 cases per year and this is rising at a rate of 1% year on year, while globally over 400,000 patients are diagnosed annually. Current standard treatment requires surgical removal of the uterus, tubes, and ovaries (hysterectomy). Clinical management guidelines for early-stage endometrial cancer also prescribe lymph node dissection to determine (via histopathology) the extent of the disease, however, this may lead to treatment that is more extensive than necessary.
We are currently running a phase III randomised clinical trial exploring the risks and benefits of lymph node dissection in clinical stage I endometrial cancer. The primary outcome of the trial is to determine the probability of disease-free survival at 4 years.
This project focuses on assessing:
Obermair, Andreas, Nicklin, Jim, Gebski, Val, Hayes, Sandra C., Graves, Nicholas, Mileshkin, Linda, Lin, Ming Yin, Beale, Phillip, Baxter, Eva, Robledo, Kristy, Salomon, Carlos, Hanna, George B. and Janda, Monika (2021). A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecologic Cancer, 31 (12), 1595-1601. doi: 10.1136/ijgc-2021-003029
Fertility-sparing treatment in early endometrial cancer: current state and future strategies
Obermair, Andreas, Baxter, Eva, Brennan, Donal J., McAlpine, Jessica N., Muellerer, Jennifer J., Amant, Frédéric, van Gent, Mignon D. J. M., Coleman, Robert L., Westin, Shannon N., Yates, Melinda S., Krakstad, Camilla and Janda, Monika (2020). Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 63 (4), 417-431. doi: 10.5468/ogs.19169
Improving response to progestin treatment of low-grade endometrial cancer
Baxter, Eva, Brennan, Donal J, McAlpine, Jessica N, Mueller, Jennifer J, Amant, Frédéric, van Gent, Mignon D J M, Huntsman, David G, Coleman, Robert L, Westin, Shannon N, Yates, Melinda S, Krakstad, Camilla, Quinn, Michael A, Janda, Monika and Obermair, Andreas (2020). Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecologic Cancer, 30 (11) ijgc-2020-001309, ijgc-2020. doi: 10.1136/ijgc-2020-001309
Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer
Donohoe, Fionán, Wilkinson, Michael, Baxter, Eva and Brennan, Donal J. (2020). Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer. International Journal of Molecular Sciences, 21 (4) 1241, 1-19. doi: 10.3390/ijms21041241
Casciello, Francesco, Al-Ejeh, Fares, Miranda, Mariska, Kelly, Greg, Baxter, Eva, Windloch, Karolina, Gannon, Frank and Lee, Jason S. (2020). G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics, 10 (10), 4515-4529. doi: 10.7150/thno.41453
Molecular basis of distinct oestrogen responses in endometrial and breast cancer
Baxter, Eva, Windloch, Karolina, Kelly, Greg, Lee, Jason S., Gannon, Frank and Brennan, Donal (2019). Molecular basis of distinct oestrogen responses in endometrial and breast cancer. Endocrine-Related Cancer, 26 (1), 31-46. doi: 10.1530/ERC-17-0563
Jacquelin, Sebastien, Straube, Jasmin, Cooper, Leanne, Vu, Therese, Song, Axia, Bywater, Megan, Baxter, Eva, Heidecker, Matthew, Wackrow, Brad, Porter, Amy, Ling, Victoria, Green, Joanne, Austin, Rebecca, Kazakoff, Stephen, Waddell, Nicola, Hesson, Luke B., Pimanda, John E., Stegelmann, Frank, Bullinger, Lars, Döhner, Konstanze, Rampal, Raajit K., Heckl, Dirk, Hill, Geoffrey R. and Lane, Steven W. (2018). Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood, 132 (26), blood-2018. doi: 10.1182/blood-2018-04-846220
Obermair, Andreas, Brennan, Donal J., Baxter, Eva, Armes, Jane E., Gebski, Val and Janda, Monika (2016). Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecologic Oncology Research and Practice, 3 (1), 1. doi: 10.1186/s40661-016-0023-8
Epigenetic regulation in cancer progression
Baxter, Eva, Windloch, Karolina, Gannon, Frank and Lee, Jason S. (2014). Epigenetic regulation in cancer progression. Cell & Bioscience, 4 (1) 45, 45. doi: 10.1186/2045-3701-4-45
(2024–2028) NHMRC Clinical Trials and Cohort Studies Grants
Note for students: The possible research projects listed on this page may not be comprehensive or up to date. Always feel free to contact the staff for more information, and also with your own research ideas.
Biomarkers in gynaecological cancer
Gynaecological cancers are the third most common cancer type diagnosed in Australian women. Each year over 6,700 Australian women and girls are diagnosed with gynaecological cancer and almost a third will not survive their disease.
We have a PhD opportunity available at the Queensland Centre for Gynaecological Cancer (QCGC) Research focusing on discovering and validating biomarkers that improve outcomes for women with gynaecological cancer. This project will involve working with clinical samples, conducting laboratory work, and analysing data.
The successful applicant will work as part of the QCGC Research team at the Centre for Clinical Research, as well as collaborate with researchers, clinicians, consumers, and stakeholders from other organisations, including hospitals, pathology providers and the community.
Improving outcomes for women experiencing gynaecological cancer
Endometrial cancer originates from the inner layer of the uterus and is the fifth most common cancer in women. In Australia, the incidence is >3,000 cases per year and this is rising at a rate of 1% year on year, while globally over 400,000 patients are diagnosed annually. Current standard treatment requires surgical removal of the uterus, tubes, and ovaries (hysterectomy). Clinical management guidelines for early-stage endometrial cancer also prescribe lymph node dissection to determine (via histopathology) the extent of the disease, however, this may lead to treatment that is more extensive than necessary.
We are currently running a phase III randomised clinical trial exploring the risks and benefits of lymph node dissection in clinical stage I endometrial cancer. The primary outcome of the trial is to determine the probability of disease-free survival at 4 years.
This project focuses on assessing: